医学
2型糖尿病
兴奋剂
低血糖
不利影响
胰高血糖素样肽1受体
安慰剂
糖尿病
药方
安全概况
减肥
内科学
临床试验
血糖性
药理学
受体
内分泌学
肥胖
替代医学
病理
作者
Pamela Kushner,John E. Anderson,J. Simon,Kristina S. Boye,Klaus Ranta,Amelia Torcello‐Gómez,Joshua A. Levine
出处
期刊:Clinical Diabetes
[American Diabetes Association]
日期:2022-11-29
卷期号:41 (2): 258-272
被引量:3
摘要
This article reviews the efficacy and safety data of tirzepatide, a once-weekly, novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 (GLP-1) receptor agonist approved in the United States, the European Union, and other regions for the treatment of type 2 diabetes. All doses of tirzepatide demonstrated superiority in reducing A1C and body weight from baseline versus placebo or active comparators. The safety profile of tirzepatide was consistent with that of the GLP-1 receptor agonist class, with mild to moderate and transient gastrointestinal side effects being the most common adverse events. With clinically and statistically significant reductions in A1C and body weight without increased risk of hypoglycemia in various populations, tirzepatide has demonstrated potential as a first-in-class treatment option for many people with type 2 diabetes.
科研通智能强力驱动
Strongly Powered by AbleSci AI